Physician profile
Devon R Ballard
NPI 1548203664
$11,999.94
in general payments reported to CMS, 2019-2025
47 companies · $1,445 in 2025
The $1,445 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,215 · 2020: $1,327 · 2021: $1,695 · 2022: $2,265 · 2023: $2,259 · 2024: $1,795 · 2025: $1,445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,498.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,329.31 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $1,178.99 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $1,159.45 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,126.13 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $772.28 | 2019-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $761.85 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $649.39 | 2019-2025 | |
| Abbott Laboratories | $526.24 | 2022-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $419.31 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $404.77 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $339.70 | 2019-2025 | Veozah |
| Amarin Pharma, INC. | $324.36 | 2019-2022 | |
| Antares Pharma, INC. | $315.70 | 2020-2025 | Xyosted, Nocdurna, Tlando |
| Corium, LLC | $303.45 | 2022-2024 | Azstarys |
| Biohaven Pharmaceutical Holding Company Ltd. | $232.55 | 2022 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devon Ballard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.